BioSpace News Archive

The strong momentum continues: all near-term business targets for 2021 achieved, rapid customer project intake accelerating, commercial team in Europe expanded, more line capacity added, ISMS certificate received, and a new near-term business target introduced: “Biologics pilot line for GMP in 2022".

The members of the Nomination Committee for BioInvent International AB:s Annual General Meeting in 2022 have now been appointed.

Gilead Sciences Canada, Inc. announced that Health Canada has granted Notice of Compliance to TRODELVY® for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior therapies, at least one of them for metastatic disease.[ii].

Pfizer Inc. and BioNTech SE announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on the administration of the companies’ COVID-19 vaccine COMIRNATY® in children 5 to under 12 years of age.

IASO Biotherapeutics announced on Oct 26, 2021 that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted the Orphan Drug Designation to the company’s in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor -T cell therapy for the treatment of acute lymphoblastic leukemia.

Antengene Corporation Limited announced that according to the latest semi-annual review results of the world’s leading index company MSCI, Antengene has been included in the MSCI Global Small Cap Indexes - MSCI China Index constituent stocks.

Pixium Vision SA announces that Lloyd Diamond, Chief Executive Officer of Pixium Vision, and Offer Nonhoff, Chief Financial Officer of Pixium Vision, will present at the Ophthalmology Day organized by BTIG, taking place virtually on Tuesday, 30 November 2021.

The Directors of Biotron Limited are pleased to announce that the Company’s lead clinical asset, BIT225, has demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal and cell-based studies performed at The SCRIPPS Research Institute, La Jolla, CA, USA.

Elekta announced that its latest African order for Elekta Unity MR-Linac comes less than six months after the company introduced its ACCESS 2025 strategy, which includes giving more than 300 million people access to radiation therapy with the addition of 800 to 1,000 additional Elekta linacs in underserved markets.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced that an investigator-led, Phase 2 trial initiated to evaluate the immunogenicity and safety of heterologous and homologous COVID-19 booster vaccines.